Component

Human MTNR1B rs10830963 G risk allele

Human MTNR1B rs10830963 G risk allele. Species, exposure and limitations are retained in each linked claim.

7 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Risk G-allele carriers had increased MTNR1B expression in human islets.

    Human MTNR1B rs10830963 G risk allele → Human islet MTNR1B expression source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/melatonin-research/27185156.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "61fcf7c730c1349e5b306e5c9cfcabcb2905290d7f8762cbfba06f2b5fccaded", "start_char": 0, "end_char": 1043, "text_sha256": "61fcf7c730c1349e5b306e5c9cfcabcb2905290d7f8762cbfba06f2b5fccaded"}
    experimental_model
    Human islet genetics, cell experiments and recall-by-genotype intervention
    exposure
    Risk G allele, receptor overexpression and melatonin exposure
    limitations
    Genotype associations, cultured-cell manipulation and human intervention are separate evidence types. Do not generalize islet signaling to every tissue.
    nutrient_topic
    Melatonin research collection; topical membership is not evidence of a direct dietary effect. · Melatonin
    organism
    Human islets and volunteers; separate insulin-cell and mouse experiments
    plain_language
    A receptor-gene variant can change the strength of a hormone response.
    primary_references
    [melatonin-p27185156] Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. (2016). https://pubmed.ncbi.nlm.nih.gov/27185156/ DOI: 10.1016/j.cmet.2016.04.009
    tissue_or_cell_type
    MTNR1B signaling and insulin secretion

    Melatonin: synthesis, receptors, circadian timing and nutrient interactions (2026-09-17) · lines 1098–1109

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Human islet genetics, cell experiments and recall-by-genotype intervention · source_derived_draft · unverified_draft

    ### melatonin-mtnr1b-risk-expression Risk G-allele carriers had increased MTNR1B expression in human islets. Condition category: normal nutrient_topic: Melatonin research collection; topical membership is not evidence of a direct dietary effect. plain_language: A receptor-gene variant can change the strength of a hormone response. organism: Human islets and volunteers; separate insulin-cell and mouse experiments tissue_or_cell_type: MTNR1B signaling and insulin secretion experimental_model: Human islet genetics, cell experiments and recall-by-genotype intervention limitations: Genotype associations, cultured-cell manipulation and human intervention are separate evidence types. Do not generalize islet signaling to every tissue. exposure: Risk G allele, receptor overexpression and melatonin exposure evidence_span: {"source_cache": "artifacts/melatonin-research/27185156.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "61fcf7c730c1349e5b306e5c9cfcabcb2905290d7f8762cbfba06f2b5fccaded", "start_char": 0, "end_char": 1043, "text_sha256": "61fcf7c730c1349e5b306e5c9cfcabcb2905290d7f8762cbfba06f2b5fccaded"} [melatonin-p27185156] Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. (2016). https://pubmed.ncbi.nlm.nih.gov/27185156/ DOI: 10.1016/j.cmet.2016.04.009
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. First-phase beta-cell glucose responsiveness was suppressed by about 40% in risk carriers.

    Melatonin → First-phase beta-cell responsiveness to glucose source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/melatonin-research/42346809.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6", "start_char": 0, "end_char": 1941, "text_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6"}
    experimental_model
    Randomized double-blind placebo-controlled crossover physiology trial
    exposure
    5 mg oral melatonin; five-day laboratory protocol
    limitations
    Small genotype-stratified acute study published in 2026. Stronger carrier findings are not a population-wide diabetes risk estimate or evidence about all chronic formulations.
    nutrient_topic
    Melatonin research collection; topical membership is not evidence of a direct dietary effect. · Melatonin
    organism
    21 healthy European-ancestry participants: 10 risk carriers, 11 noncarriers
    plain_language
    The early insulin-secretion response was specifically impaired.
    primary_references
    [melatonin-p42346809] Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. (2026). https://pubmed.ncbi.nlm.nih.gov/42346809/ DOI: 10.2337/dc26-0164
    tissue_or_cell_type
    Insulin-modified IV glucose test and beta-cell modeling

    Melatonin: synthesis, receptors, circadian timing and nutrient interactions (2026-09-17) · lines 1202–1213

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled crossover physiology trial · source_derived_draft · unverified_draft

    ### melatonin-2026-first-phase First-phase beta-cell glucose responsiveness was suppressed by about 40% in risk carriers. Condition category: normal nutrient_topic: Melatonin research collection; topical membership is not evidence of a direct dietary effect. plain_language: The early insulin-secretion response was specifically impaired. organism: 21 healthy European-ancestry participants: 10 risk carriers, 11 noncarriers tissue_or_cell_type: Insulin-modified IV glucose test and beta-cell modeling experimental_model: Randomized double-blind placebo-controlled crossover physiology trial limitations: Small genotype-stratified acute study published in 2026. Stronger carrier findings are not a population-wide diabetes risk estimate or evidence about all chronic formulations. exposure: 5 mg oral melatonin; five-day laboratory protocol evidence_span: {"source_cache": "artifacts/melatonin-research/42346809.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6", "start_char": 0, "end_char": 1941, "text_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6"} [melatonin-p42346809] Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. (2026). https://pubmed.ncbi.nlm.nih.gov/42346809/ DOI: 10.2337/dc26-0164
    Complete structured claim and evidence

  2. Melatonin worsened glucose tolerance in MTNR1B risk carriers, while the corresponding impairment was not significant in noncarriers.

    Melatonin → Glucose tolerance source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/melatonin-research/42346809.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6", "start_char": 0, "end_char": 1941, "text_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6"}
    experimental_model
    Randomized double-blind placebo-controlled crossover physiology trial
    exposure
    5 mg oral melatonin; five-day laboratory protocol
    limitations
    Small genotype-stratified acute study published in 2026. Stronger carrier findings are not a population-wide diabetes risk estimate or evidence about all chronic formulations.
    nutrient_topic
    Melatonin research collection; topical membership is not evidence of a direct dietary effect. · Melatonin
    organism
    21 healthy European-ancestry participants: 10 risk carriers, 11 noncarriers
    plain_language
    The recent controlled study found a genotype-dependent response.
    primary_references
    [melatonin-p42346809] Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. (2026). https://pubmed.ncbi.nlm.nih.gov/42346809/ DOI: 10.2337/dc26-0164
    tissue_or_cell_type
    Insulin-modified IV glucose test and beta-cell modeling

    Melatonin: synthesis, receptors, circadian timing and nutrient interactions (2026-09-17) · lines 1189–1200

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled crossover physiology trial · source_derived_draft · unverified_draft

    ### melatonin-2026-glucose-carriers Melatonin worsened glucose tolerance in MTNR1B risk carriers, while the corresponding impairment was not significant in noncarriers. Condition category: normal nutrient_topic: Melatonin research collection; topical membership is not evidence of a direct dietary effect. plain_language: The recent controlled study found a genotype-dependent response. organism: 21 healthy European-ancestry participants: 10 risk carriers, 11 noncarriers tissue_or_cell_type: Insulin-modified IV glucose test and beta-cell modeling experimental_model: Randomized double-blind placebo-controlled crossover physiology trial limitations: Small genotype-stratified acute study published in 2026. Stronger carrier findings are not a population-wide diabetes risk estimate or evidence about all chronic formulations. exposure: 5 mg oral melatonin; five-day laboratory protocol evidence_span: {"source_cache": "artifacts/melatonin-research/42346809.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6", "start_char": 0, "end_char": 1941, "text_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6"} [melatonin-p42346809] Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. (2026). https://pubmed.ncbi.nlm.nih.gov/42346809/ DOI: 10.2337/dc26-0164
    Complete structured claim and evidence

  3. Risk carriers had no insulin-induced hypoglycemia events with melatonin versus seven with placebo in the test.

    Melatonin → Hypoglycemia during an insulin-modified glucose test source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/melatonin-research/42346809.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6", "start_char": 0, "end_char": 1941, "text_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6"}
    experimental_model
    Randomized double-blind placebo-controlled crossover physiology trial
    exposure
    5 mg oral melatonin; five-day laboratory protocol
    limitations
    Small genotype-stratified acute study published in 2026. Stronger carrier findings are not a population-wide diabetes risk estimate or evidence about all chronic formulations.
    nutrient_topic
    Melatonin research collection; topical membership is not evidence of a direct dietary effect. · Melatonin
    organism
    21 healthy European-ancestry participants: 10 risk carriers, 11 noncarriers
    plain_language
    This experimental observation is not evidence to use melatonin as a hypoglycemia treatment.
    primary_references
    [melatonin-p42346809] Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. (2026). https://pubmed.ncbi.nlm.nih.gov/42346809/ DOI: 10.2337/dc26-0164
    tissue_or_cell_type
    Insulin-modified IV glucose test and beta-cell modeling

    Melatonin: synthesis, receptors, circadian timing and nutrient interactions (2026-09-17) · lines 1228–1239

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled crossover physiology trial · source_derived_draft · unverified_draft

    ### melatonin-2026-hypoglycemia Risk carriers had no insulin-induced hypoglycemia events with melatonin versus seven with placebo in the test. Condition category: normal nutrient_topic: Melatonin research collection; topical membership is not evidence of a direct dietary effect. plain_language: This experimental observation is not evidence to use melatonin as a hypoglycemia treatment. organism: 21 healthy European-ancestry participants: 10 risk carriers, 11 noncarriers tissue_or_cell_type: Insulin-modified IV glucose test and beta-cell modeling experimental_model: Randomized double-blind placebo-controlled crossover physiology trial limitations: Small genotype-stratified acute study published in 2026. Stronger carrier findings are not a population-wide diabetes risk estimate or evidence about all chronic formulations. exposure: 5 mg oral melatonin; five-day laboratory protocol evidence_span: {"source_cache": "artifacts/melatonin-research/42346809.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6", "start_char": 0, "end_char": 1941, "text_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6"} [melatonin-p42346809] Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. (2026). https://pubmed.ncbi.nlm.nih.gov/42346809/ DOI: 10.2337/dc26-0164
    Complete structured claim and evidence

  4. Risk carriers showed a slower insulin-induced decline in second-phase insulin secretion during melatonin exposure.

    Melatonin → Suppression of insulin secretion by exogenous insulin source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/melatonin-research/42346809.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6", "start_char": 0, "end_char": 1941, "text_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6"}
    experimental_model
    Randomized double-blind placebo-controlled crossover physiology trial
    exposure
    5 mg oral melatonin; five-day laboratory protocol
    limitations
    Small genotype-stratified acute study published in 2026. Stronger carrier findings are not a population-wide diabetes risk estimate or evidence about all chronic formulations.
    nutrient_topic
    Melatonin research collection; topical membership is not evidence of a direct dietary effect. · Melatonin
    organism
    21 healthy European-ancestry participants: 10 risk carriers, 11 noncarriers
    plain_language
    Regulation by insulin itself changed as well as the response to glucose.
    primary_references
    [melatonin-p42346809] Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. (2026). https://pubmed.ncbi.nlm.nih.gov/42346809/ DOI: 10.2337/dc26-0164
    tissue_or_cell_type
    Insulin-modified IV glucose test and beta-cell modeling

    Melatonin: synthesis, receptors, circadian timing and nutrient interactions (2026-09-17) · lines 1215–1226

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled crossover physiology trial · source_derived_draft · unverified_draft

    ### melatonin-2026-insulin-feedback Risk carriers showed a slower insulin-induced decline in second-phase insulin secretion during melatonin exposure. Condition category: normal nutrient_topic: Melatonin research collection; topical membership is not evidence of a direct dietary effect. plain_language: Regulation by insulin itself changed as well as the response to glucose. organism: 21 healthy European-ancestry participants: 10 risk carriers, 11 noncarriers tissue_or_cell_type: Insulin-modified IV glucose test and beta-cell modeling experimental_model: Randomized double-blind placebo-controlled crossover physiology trial limitations: Small genotype-stratified acute study published in 2026. Stronger carrier findings are not a population-wide diabetes risk estimate or evidence about all chronic formulations. exposure: 5 mg oral melatonin; five-day laboratory protocol evidence_span: {"source_cache": "artifacts/melatonin-research/42346809.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6", "start_char": 0, "end_char": 1941, "text_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6"} [melatonin-p42346809] Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. (2026). https://pubmed.ncbi.nlm.nih.gov/42346809/ DOI: 10.2337/dc26-0164
    Complete structured claim and evidence

  5. The human recall-by-genotype study found greater insulin-secretion reduction and glucose elevation in G-allele carriers.

    Melatonin → Insulin secretion source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/melatonin-research/27185156.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "61fcf7c730c1349e5b306e5c9cfcabcb2905290d7f8762cbfba06f2b5fccaded", "start_char": 0, "end_char": 1043, "text_sha256": "61fcf7c730c1349e5b306e5c9cfcabcb2905290d7f8762cbfba06f2b5fccaded"}
    experimental_model
    Human islet genetics, cell experiments and recall-by-genotype intervention
    exposure
    Risk G allele, receptor overexpression and melatonin exposure
    limitations
    Genotype associations, cultured-cell manipulation and human intervention are separate evidence types. Do not generalize islet signaling to every tissue.
    nutrient_topic
    Melatonin research collection; topical membership is not evidence of a direct dietary effect. · Melatonin
    organism
    Human islets and volunteers; separate insulin-cell and mouse experiments
    plain_language
    A response can vary with receptor genotype.
    primary_references
    [melatonin-p27185156] Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. (2016). https://pubmed.ncbi.nlm.nih.gov/27185156/ DOI: 10.1016/j.cmet.2016.04.009
    tissue_or_cell_type
    MTNR1B signaling and insulin secretion

    Melatonin: synthesis, receptors, circadian timing and nutrient interactions (2026-09-17) · lines 1137–1148

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Human islet genetics, cell experiments and recall-by-genotype intervention · source_derived_draft · unverified_draft

    ### melatonin-genotype-human-insulin The human recall-by-genotype study found greater insulin-secretion reduction and glucose elevation in G-allele carriers. Condition category: normal nutrient_topic: Melatonin research collection; topical membership is not evidence of a direct dietary effect. plain_language: A response can vary with receptor genotype. organism: Human islets and volunteers; separate insulin-cell and mouse experiments tissue_or_cell_type: MTNR1B signaling and insulin secretion experimental_model: Human islet genetics, cell experiments and recall-by-genotype intervention limitations: Genotype associations, cultured-cell manipulation and human intervention are separate evidence types. Do not generalize islet signaling to every tissue. exposure: Risk G allele, receptor overexpression and melatonin exposure evidence_span: {"source_cache": "artifacts/melatonin-research/27185156.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "61fcf7c730c1349e5b306e5c9cfcabcb2905290d7f8762cbfba06f2b5fccaded", "start_char": 0, "end_char": 1043, "text_sha256": "61fcf7c730c1349e5b306e5c9cfcabcb2905290d7f8762cbfba06f2b5fccaded"} [melatonin-p27185156] Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. (2016). https://pubmed.ncbi.nlm.nih.gov/27185156/ DOI: 10.1016/j.cmet.2016.04.009
    Complete structured claim and evidence

  6. Glucose AUC was about 8.3% higher in the late condition, with greater impairment in MTNR1B risk carriers.

    Late-evening glucose challenge relative to habitual bedtime → Glucose area under the curve after glucose challenge source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/melatonin-research/35015083.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "14878cd566ac009dde6fd0a6cc78adf1a4b48cfb2bc09e262568c909f84f236e", "start_char": 0, "end_char": 1688, "text_sha256": "14878cd566ac009dde6fd0a6cc78adf1a4b48cfb2bc09e262568c909f84f236e"}
    experimental_model
    Randomized crossover early versus late glucose-challenge study
    exposure
    75 g OGTT four versus one hour before habitual bedtime after eight-hour fast
    limitations
    Glucose drinks simulated meal timing. Timing, endogenous melatonin and other circadian factors co-varied; the intervention did not selectively manipulate melatonin alone.
    nutrient_topic
    Melatonin research collection; topical membership is not evidence of a direct dietary effect. · Melatonin
    organism
    845 Spanish adults
    plain_language
    A meal-timing comparison can reveal susceptibility without proving melatonin is the only mediator.
    primary_references
    [melatonin-p35015083] Interplay of Dinner Timing and MTNR1B Type 2 Diabetes Risk Variant on Glucose Tolerance and Insulin Secretion: A Randomized Crossover Trial. (2022). https://pubmed.ncbi.nlm.nih.gov/35015083/ DOI: 10.2337/dc21-1314
    tissue_or_cell_type
    Endogenous melatonin and evening glucose handling

    Melatonin: synthesis, receptors, circadian timing and nutrient interactions (2026-09-17) · lines 1163–1174

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized crossover early versus late glucose-challenge study · source_derived_draft · unverified_draft

    ### melatonin-late-challenge-glucose Glucose AUC was about 8.3% higher in the late condition, with greater impairment in MTNR1B risk carriers. Condition category: normal nutrient_topic: Melatonin research collection; topical membership is not evidence of a direct dietary effect. plain_language: A meal-timing comparison can reveal susceptibility without proving melatonin is the only mediator. organism: 845 Spanish adults tissue_or_cell_type: Endogenous melatonin and evening glucose handling experimental_model: Randomized crossover early versus late glucose-challenge study limitations: Glucose drinks simulated meal timing. Timing, endogenous melatonin and other circadian factors co-varied; the intervention did not selectively manipulate melatonin alone. exposure: 75 g OGTT four versus one hour before habitual bedtime after eight-hour fast evidence_span: {"source_cache": "artifacts/melatonin-research/35015083.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "14878cd566ac009dde6fd0a6cc78adf1a4b48cfb2bc09e262568c909f84f236e", "start_char": 0, "end_char": 1688, "text_sha256": "14878cd566ac009dde6fd0a6cc78adf1a4b48cfb2bc09e262568c909f84f236e"} [melatonin-p35015083] Interplay of Dinner Timing and MTNR1B Type 2 Diabetes Risk Variant on Glucose Tolerance and Insulin Secretion: A Randomized Crossover Trial. (2022). https://pubmed.ncbi.nlm.nih.gov/35015083/ DOI: 10.2337/dc21-1314
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards